What is the recommended treatment for an enlarged prostate (prostatomegaly)?

Treatment of Enlarged Prostate (Prostatomegaly)

For men with bothersome moderate-to-severe lower urinary tract symptoms from benign prostatic hyperplasia, start with an alpha-1 blocker (tamsulosin, alfuzosin, silodosin, or terazosin) for rapid symptom relief, and add a 5-alpha reductase inhibitor (finasteride or dutasteride) if the prostate is >30 mL to prevent disease progression and reduce long-term complications. 1

Symptom Severity-Based Approach

Mild Symptoms

• Watchful waiting is appropriate for men with mild, non-bothersome symptoms 1, 2
• Offer lifestyle modifications including fluid management, caffeine/alcohol reduction, and timed voiding 1, 2

Moderate-to-Severe Symptoms

First-Line: Alpha-1 Blockers

• Provide rapid symptom improvement within days to weeks 1, 2
• Options include tamsulosin, alfuzosin, silodosin, or terazosin with similar efficacy 1
• Critical caveat: Warn patients scheduled for cataract surgery about intraoperative floppy iris syndrome, particularly with tamsulosin 1

Prostate Size-Directed Therapy

Enlarged Prostate (>30 mL or PSA >1.5 ng/mL)

Add 5-Alpha Reductase Inhibitors (5-ARIs)

• Finasteride or dutasteride reduce prostate volume by 15-25% over 6 months 1
• Prevent disease progression: reduce acute urinary retention risk and need for surgery by altering the natural history of BPH 1
• Symptom improvement is slower (3-4 points on IPSS) but sustained over years 1
• Larger prostates (>40 mL) derive greater benefit from 5-ARIs 1, 2

Combination Therapy (Alpha-blocker + 5-ARI)

• The CombAT study demonstrated superior outcomes with dutasteride plus tamsulosin over 4 years in men with enlarged prostates 1
• Combines rapid symptom relief (alpha-blocker) with long-term disease modification (5-ARI) 1

Important 5-ARI Considerations

• PSA levels decrease by ~50% after 1 year; double the measured PSA value when screening for prostate cancer 1
• Counsel patients on slower onset of action compared to alpha-blockers 1
• Dutasteride inhibits both 5-AR type I and II (95% DHT reduction) versus finasteride's type II only (70% DHT reduction), though clinical outcomes are similar 1

Additional Pharmacologic Options

For Persistent Storage Symptoms

• Antimuscarinics (tolterodine, solifenacin) or beta-3 agonists (mirabegron) for men with predominant urgency, frequency, or overactive bladder symptoms 1, 2
• Can be combined with alpha-blockers 1

Phosphodiesterase-5 Inhibitors

• Tadalafil reduces LUTS to a similar extent as alpha-blockers and improves erectile dysfunction 2

For Nocturia Due to Nocturnal Polyuria

• Desmopressin can be considered 2

Surgical Intervention Indications

Surgery is indicated for:

• Absolute indications: Refractory urinary retention, recurrent UTIs, bladder stones, renal insufficiency due to BPH, or gross hematuria refractory to medical therapy 2
• Relative indication: Drug treatment-resistant bothersome LUTS 2

Surgical Options by Prostate Size:

• <30 mL: Transurethral incision of the prostate (TUIP) 2
• 30-80 mL: Transurethral resection of the prostate (TURP) remains the standard; bipolar TURP and laser treatments are alternatives 2
• >80 mL: Open prostatectomy or holmium laser enucleation 2

Perioperative 5-ARI Use

• Consider preoperative 5-ARIs to reduce intraoperative bleeding and transfusion risk during TURP 1

Critical Clinical Pitfalls

• Don't overlook coexisting conditions: Rule out urinary tract infection, prostate cancer, bladder cancer, neurogenic bladder, and urethral stricture 3
• Obtain objective prostate size measurement via transrectal ultrasound or cross-sectional imaging before prescribing 5-ARIs; they are ineffective in prostates <30 mL 1
• Screen for cardiovascular disease before prescribing alpha-blockers due to potential orthostatic hypotension 1
• Document baseline sexual function: Both alpha-blockers and 5-ARIs can affect ejaculation and erectile function 1